The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Separating the winners from the value traps is a tough challenge, and that’s where StockStory comes in. Our job is to find you high-quality companies that will stand the test of time. That said, here are two value stocks trading at big discounts to their intrinsic values and one facing an uphill battle.
One Value Stock to Sell:
Everforth (EFOR)
Forward P/E Ratio: 4.8x
Evolving from its roots in IT staffing to become a high-end technology consulting powerhouse, Everforth (EFOR) provides specialized IT consulting services and staffing solutions to Fortune 1000 companies and U.S. federal government agencies.
Why Is EFOR Risky?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 4.6% annually over the last two years
- Estimated sales for the next 12 months are flat and imply a softer demand environment
- Earnings per share have contracted by 2.5% annually over the last five years, a headwind for returns as stock prices often echo long-term EPS performance
Everforth’s stock price of $17.68 implies a valuation ratio of 4.8x forward P/E. If you’re considering EFOR for your portfolio, see our FREE research report to learn more.
Two Value Stocks to Watch:
Allegion (ALLE)
Forward P/E Ratio: 14.5x
Allegion plc (NYSE: ALLE) is a provider of security products and solutions that keep people and assets safe and secure in various environments.
Why Does ALLE Stand Out?
- Highly efficient business model is illustrated by its impressive 19.6% operating margin, and its profits increased over the last five years as it scaled
- Robust free cash flow margin of 14.5% gives it many options for capital deployment, and its rising cash conversion increases its margin of safety
- Stellar returns on capital showcase management’s ability to surface highly profitable business ventures
At $128.79 per share, Allegion trades at 14.5x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.
AbbVie (ABBV)
Forward P/E Ratio: 15.4x
Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE: ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.
Why Do We Like ABBV?
- Enormous revenue base of $62.82 billion gives it economies of scale and advantages over new entrants due to the industry’s regulatory complexity
- Strong free cash flow margin of 35.7% enables it to reinvest or return capital consistently
- ROIC punches in at 17.5%, illustrating management’s expertise in identifying profitable investments
AbbVie is trading at $234.75 per share, or 15.4x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
